Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $36.70.
Several equities analysts have issued reports on ALKS shares. HC Wainwright lifted their price objective on Alkermes from $35.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 price target on shares of Alkermes in a report on Thursday, July 25th. JPMorgan Chase & Co. upped their price target on shares of Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a research report on Thursday, July 25th. Robert W. Baird raised their price objective on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Finally, StockNews.com raised shares of Alkermes from a “hold” rating to a “buy” rating in a research note on Sunday, July 28th.
Get Our Latest Stock Analysis on ALKS
Institutional Investors Weigh In On Alkermes
Alkermes Trading Down 0.5 %
Shares of Alkermes stock opened at $25.94 on Thursday. Alkermes has a 12-month low of $22.01 and a 12-month high of $32.88. The stock has a market capitalization of $4.39 billion, a P/E ratio of 10.25, a price-to-earnings-growth ratio of 0.56 and a beta of 0.47. The company has a 50-day simple moving average of $25.13 and a 200 day simple moving average of $26.03. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Alkermes had a net margin of 19.15% and a return on equity of 23.20%. The firm had revenue of $399.13 million for the quarter, compared to analysts’ expectations of $393.30 million. During the same period in the prior year, the firm earned $0.38 earnings per share. The company’s quarterly revenue was down 35.4% compared to the same quarter last year. Research analysts expect that Alkermes will post 2.36 earnings per share for the current fiscal year.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
- Five stocks we like better than Alkermes
- Most Volatile Stocks, What Investors Need to Know
- How to Invest in Silver: A Beginner’s Guide
- What is a Bond Market Holiday? How to Invest and Trade
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.